OptimizeRx
OPRX
147 hedge funds and large institutions have $428M invested in OptimizeRx in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 66 increasing their positions, 39 reducing their positions, and 24 closing their positions.
207% more call options, than puts
Call options by funds: $23M | Put options by funds: $7.48M
69% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.71% less ownership
Funds ownership: 86.79% → 86.08% (-0.71%)
4% less funds holding
Funds holding: 153 → 147 (-6)
13% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 24
27% less capital invested
Capital invested by funds: $585M → $428M (-$157M)
Top Buyers
Top Sellers
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.24M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$3.61M |
| 3 |
Two Sigma Investments
New York
|
-$3.21M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$2.66M |
| 5 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
-$1.89M |
OPRX Hedge Fund Activity: Q2 2022 in Review
147 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q2 2022, worth a combined $428M — down 27% from $585M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of OPRX and 21 opened new positions — a net loss of 3 holders — while 39 trimmed existing stakes and 66 added.
The largest buyer was Kornitzer Capital Management, opening a new position worth an estimated $6.83M. The largest seller was Driehaus Capital Management, cutting an estimated $4.24M.
- 147 institutional investors held OptimizeRx (OPRX) as of Q2 2022, down from 153 in Q1 2022.
- Funds reported $428M of OptimizeRx stock for Q2 2022, down 27% quarter-over-quarter.
- 21 funds opened new OptimizeRx positions in Q2 2022 and 24 closed out, a net change of -3 holders.
- The largest OptimizeRx buyer in Q2 2022 was Kornitzer Capital Management, an estimated $6.83M added.
- The largest OptimizeRx seller in Q2 2022 was Driehaus Capital Management, an estimated $4.24M sold.
Based on aggregated 13F filings for Q2 2022.